4.7 Article

Identification and characterization of IgG4-associated autoimmune hepatitis

Journal

LIVER INTERNATIONAL
Volume 30, Issue 2, Pages 222-231

Publisher

WILEY
DOI: 10.1111/j.1478-3231.2009.02092.x

Keywords

autoimmune hepatitis; IgG4; steroid treatment

Funding

  1. Takeda Science Foundation
  2. Ichiro Kanehara Memorial Foundation
  3. Astellas Foundation for Research on Metabolic Disorders
  4. Yakult Bioscience Foundation
  5. Sumitomo Foundation
  6. Pancreas Research Foundation of Japan
  7. Uehara Memorial Foundation
  8. Grants-in-Aid for Scientific Research [21590532] Funding Source: KAKEN

Ask authors/readers for more resources

Background Autoimmune hepatitis (AIH) and autoimmune pancreatitis (AIP) share clinical and pathological features such as high serum levels of immunoglobulin (Ig) G and autoantibodies, and lymphoplasmacytic infiltration, suggesting the presence of common immunological abnormalities. However, little is known about the possible involvement of IgG4, a hallmark of AIP, in AIH. Aims In this study, we examined whether the IgG4 response contributes to the histopathological and clinical findings in AIH. Methods Liver sections from 26 patients with AIH, 10 patients with primary biliary cirrhosis (PBC), three patients with primary sclerosing cholangitis (PSC) and 20 chronic hepatitis patients with hepatitis C virus (HCV) infection were immunostained for IgG4. We investigated the relationship among the histopathology, the responses to steroid therapy and the IgG4 staining. Results Nine of the 26 liver specimens from patients with AIH showed positive staining for IgG4 whereas none of the 10 samples from patients with PBC, the three samples from patients with PSC or the 20 samples from patients with HCV hepatitis were positive. Patients with IgG4-positive AIH also showed increased serum levels of IgG. The numbers of T cells, B cells and plasma cells were significantly increased in the livers of patients with IgG4-positive AIH as compared with those patients with IgG4-negative AIH. Patients with IgG4-positive AIH also showed a marked response to prednisolone therapy. Conclusions AIH may be classified into either an IgG4-associated type or an IgG4 non-associated type with the former showing a marked response to prednisolone treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Ann-Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos Lopez Lopez, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong-Won Park, Daniel Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni

Summary: The study aimed to validate objective response as an independent predictor of overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC) receiving systemic anti-angiogenic therapy. The results showed that objective response assessed by investigator-assessed mRECIST could predict the survival of patients. Further studies are needed to confirm this finding.

JOURNAL OF HEPATOLOGY (2023)

Article Oncology

Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety

Philippe Merle, Masatoshi Kudo, Stanimira Krotneva, Kirhan Ozgurdal, Yun Su, Irina Proskorovsky

Summary: This study compared the efficacy and safety of regorafenib and cabozantinib in the second-line treatment of advanced hepatocellular carcinoma. The results showed that regorafenib had a favorable overall survival, lower rates of dose reduction and treatment discontinuation due to adverse events, and lower rates of severe diarrhea and fatigue compared to cabozantinib.

LIVER CANCER (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Artificial intelligence models for the diagnosis and management of liver diseases

Naoshi Nishida, Masatoshi Kudo

Summary: With the development of advanced methods for diagnosis and treatment, the complexity of medical data has increased, leading to the potential for misinterpretation and serious consequences. Artificial intelligence (AI) can help avoid human errors and has shown promising results in diagnosing and managing liver diseases. This paper summarizes recent advances in AI for liver disease and introduces the use of AI in diagnosing liver tumors using B-mode ultrasonography.

ULTRASONOGRAPHY (2023)

Article Oncology

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mara Persano, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Stefano Cascinu, Alessandro Cucchetti

Summary: This retrospective multi-center study compared the clinical efficacy and safety of lenvatinib and atezolizumab plus bevacizumab as a first-line treatment for unresectable HCC. The results showed that atezolizumab plus bevacizumab did not have a significant survival advantage over lenvatinib overall. However, lenvatinib had a higher overall survival rate in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease, while atezolizumab plus bevacizumab had a higher overall survival rate in patients with viral hepatitis. After adjusting for population, atezolizumab plus bevacizumab provided better safety profile for most adverse events.

EUROPEAN JOURNAL OF CANCER (2023)

Article Gastroenterology & Hepatology

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study

Naoya Kato, Masatoshi Kudo, Kaoru Tsuchiya, Atsushi Hagihara, Kazushi Numata, Hiroshi Aikata, Yoshitaka Inaba, Shunsuke Kondo, Kenta Motomura, Naohiro Okano, Masafumi Ikeda, Manabu Morimoto, Shingo Kuroda, Akiko Kimura

Summary: Cabozantinib demonstrated efficacy and manageable safety profile in Japanese patients with advanced HCC. The median PFS was 7.4 months in the prior-sorafenib cohort and 3.6 months in the sorafenib-naive cohort. Disease control rate was 85.0% and 64.3% in the prior-sorafenib and sorafenib-naive cohorts, respectively. The most common adverse events were palmar-plantar erythrodysesthesia syndrome, diarrhea, hypertension, and decreased appetite. No new safety concerns were identified.

HEPATOLOGY RESEARCH (2023)

Review Oncology

Imaging Diagnosis of various HCC subtypes and Its Hypervascular Mimics: Differential Diagnosis Based on Conventional Interpretation and Artificial Intelligence

Yasunori Minami, Naoshi Nishida, Masatoshi Kudo

Summary: This article discusses the imaging characteristics and differential diagnosis of hepatocellular carcinoma and other hypervascular liver lesions. Artificial intelligence in medical imaging analysis shows promise as a decision support tool, but further validation is needed.

LIVER CANCER (2023)

Review Oncology

Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review

Arndt Vogel, Robin Katie Kelley, Philip Johnson, Philippe Merle, Thomas Yau, Masatoshi Kudo, Tim Meyer, Lorenza Rimassa

Summary: A systematic literature review reveals the importance of liver function assessments in predicting disease prognosis and response to systemic anticancer therapy in patients with advanced hepatocellular carcinoma. The study supports liver function as a prognostic marker and highlights the value of stratifying patients based on baseline liver function in clinical trials for aHCC.

LIVER CANCER (2023)

Article Oncology

IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III Study

Masatoshi Kudo, Richard S. S. Finn, Peter R. R. Galle, Andrew X. X. Zhu, Michel Ducreux, Ann-Lii Cheng, Masafumi Ikeda, Kaoru Tsuchiya, Ken-ichi Aoki, Jing Jia, Riccardo Lencioni

Summary: The study demonstrates the efficacy and safety of atezolizumab + bevacizumab treatment in patients with baseline BCLC Stage B hepatocellular carcinoma, consistent with the overall study population.

LIVER CANCER (2023)

Review Medicine, General & Internal

Contrast-Enhanced Harmonic Endoscopic Ultrasound-Guided Puncture for the Patients with Pancreatic Masses

Yasuo Otsuka, Ken Kamata, Masatoshi Kudo

Summary: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a useful method for diagnosing pancreatic masses. The diagnostic performance of EUS-FNA can be improved by using contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS), which helps avoid fibrosis in the pancreatic mass. However, the effectiveness of CH-EUS-FNA is still a matter of debate, as only one out of eight studies showed improved sensitivity.

DIAGNOSTICS (2023)

Article Medicine, General & Internal

Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease

Takushi Manabe, Chikara Ogawa, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, Mitsushige Shibatoge, Asahiro Morishita, Masatoshi Kudo, Tsutomu Masaki

Summary: This study validated the assessment of sarcopenia using psoas muscle volume as a measure and found that sarcopenia was associated with shorter survival in patients with liver disease. The psoas muscle volume index (PMVI) may be useful in evaluating sarcopenia, including cases where sarcopenia cannot be diagnosed using the commonly used psoas muscle index (PMI).

DIAGNOSTICS (2023)

Article Medicine, General & Internal

Long-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma

Yasuo Otsuka, Yoriaki Komeda, Masayuki Takeda, Takayuki Takahama, Masashi Kono, Mamoru Takenaka, Satoru Hagiwara, Naoshi Nishida, Hiroshi Kashida, Masatoshi Kudo

Summary: A 76-year-old woman presented with lower abdominal pain and nausea. Imaging showed a soft tissue mass extending to the liver surface, diagnosed as epithelioid mesothelioma. After chemotherapy, the patient achieved long-term survival of more than 5 years.

CASE REPORTS IN MEDICINE (2023)

Article Biochemistry & Molecular Biology

Oral administration of ovalbumin protects mice from concanavalin A-induced hepatitis through suppression of interferon-gamma responses

Tomohiro Watanabe, Kosuke Minaga, Hajime Honjo, Masatoshi Kudo

Summary: The liver showed hypo-responsiveness to antigens and high doses of orally-administered ovalbumin (OVA) generated unique CD4+ T cells and tolerogenic dendritic cells that can suppress Th1 responses. OVA administration at high doses inhibited hepatitis development in mice with OVA-specific CD4+ T cells, and this was associated with downregulation of Th1 responses. The results suggest that high-dose oral antigen administration can suppress Th1-mediated hepatitis in an antigen-non-specific manner.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2023)

Article Gastroenterology & Hepatology

Report of the 23rd nationwide follow-up survey of primary liver cancer in Japan (2014-2015)

Hiroko Iijima, Masatoshi Kudo, Shoji Kubo, Masayuki Kurosaki, Michiie Sakamoto, Shuichiro Shiina, Ryosuke Tateishi, Nakashima Osamu, Takumi Fukumoto, Yutaka Matsuyama, Takamichi Murakami, Arata Takahashi, Hiroaki Miyata, Norihiro Kokudo

Summary: Data from a nationwide follow-up survey of primary liver cancer in Japan, which compiled information from 20,889 newly registered patients and 42,274 previously registered follow-up patients, showed that patients with hepatocellular carcinoma (HCC) in the 23rd survey were older at the time of clinical diagnosis, had more female patients, had more non-B non-C HCC patients, had smaller tumor diameter, and were more frequently treated with hepatectomy compared to the previous survey. The data obtained from this survey are expected to contribute to advancing clinical research and treatment of primary liver cancer worldwide.

HEPATOLOGY RESEARCH (2023)

No Data Available